Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 7092.

https://doi.org/10.1182/blood-2025-7092

Published: 2025

Journal Articles

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Blood (2025) 146 (Supplement 1): 670.

https://doi.org/10.1182/blood-2025-670

Published: 2025

Journal Articles

Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine: Phase 2 study

Hun Lee, Gregory Ravizzini, Jenna Wixom, Ayushi Chauhan, Luis Fayad, Ranjit Nair, Jason Westin, Jared Henderson, Eslam Aboismail, Christopher Flowers, Michael Wang, Luis Malpica Castillo

Blood (2025) 146 (Supplement 1): 153.

https://doi.org/10.1182/blood-2025-153

Published: 2025

Journal Articles

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

Mark Hamilton, Ajlan Al Zaki, Lei Feng, Zachary Hunzeker, Dai Chihara, Hun Lee, Chitra Hosing, Laura Ebarle, Oluwadare Ajishegiri, Jason Westin, Sairah Ahmed, Sattva Neelapu, Paolo Strati

Blood (2025) 146 (Supplement 1): 5485.

https://doi.org/10.1182/blood-2025-5485

Published: 2025

Journal Articles

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Blood (2025) 146 (Supplement 1): 5361.

https://doi.org/10.1182/blood-2025-5361

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Julio Chavez, Jason Westin, Javier Munoz, Emmanuel Bachy, Judit Jørgensen, Guilherme Perini, Daniel Morillo, Abel Costa, Parth Rao, Berengere De Moucheron, Gang Yang, Soraya Carrancio, Akshay Sudhindra, Michael Pourdehnad, Jessica Voetsch, Serena Perna, Jean-Marie Michot

Blood (2025) 146 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2025-1006

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Blood (2025) 146 (Supplement 1): 479.

https://doi.org/10.1182/blood-2025-479

Published: 2025

Journal Articles

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 477.

https://doi.org/10.1182/blood-2025-477

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Grzegorz Nowakowski, Marc Hoffmann, Javier Munoz, Jason Westin, Alejandro Martin Garcia-Sancho, Michal Kwiatek, Wojciech Jurczak, Maria Bouzani, Muhamad Alhaj Moustafa, Akshay Sudhindra, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Serena Perna, Theodoros Vassilakopoulos

Blood (2025) 146 (Supplement 1): 476.

https://doi.org/10.1182/blood-2025-476

Published: 2025

Journal Articles

Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy

Elizabeth Budde, Jason Westin, Huilai Zhang, Dai Maruyama, Eduardo M. Rego, Huangming Hong, Hideki Goto, Mark Fesler, Boone Goodgame, Zhiming Li, Adam Olszewski, Joan Ashby, Shen Yin, Wahib S. Ead, Martin Janousek, Song Pham, Connie L. Batlevi, Michael C. Wei, Won-Seog Kim

Blood (2025) 146 (Supplement 1): 5509.

https://doi.org/10.1182/blood-2025-5509

Published: 2025

Journal Articles

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Blood (2025) 146 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2025-1931

Published: 2025

Journal Articles

Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial

Dai Chihara, Paolo Strati, Preetesh Jain, Luis Fayad, Frederick Hagemeister, Maria Rodriguez, Richard Davis, Michael Wang, Sattva Neelapu, Christopher Flowers, Jason Westin

Blood (2025) 146 (Supplement 1): 5369.

https://doi.org/10.1182/blood-2025-5369

Published: 2025

Journal Articles

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Blood (2025) 146 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2025-3730

Published: 2025

Journal Articles

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3704.

https://doi.org/10.1182/blood-2025-3704

Published: 2025

Journal Articles

Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients

Blood (2025) 146 (Supplement 1): 806.

https://doi.org/10.1182/blood-2025-806

Published: 2025

Journal Articles

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5500.

https://doi.org/10.1182/blood-2025-5500

Published: 2025

Journal Articles

A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma

Paolo Strati, Lei Feng, Luis Malpica, Ranjit Nair, Ayushi Chauhan, Dai Chihara, Zachary Hunzeker, Laura Murphy, Elizabeth McChesney, Derek Waters, Jason Westin, Sattva Neelapu, Christopher Flowers

Blood (2025) 146 (Supplement 1): 3571.

https://doi.org/10.1182/blood-2025-3571

Published: 2025

Journal Articles

Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma

Rahul Shah, Ruitao Lin, Amanda Mason, Lauren Johnson, Luis Malpica, Paolo Strati, Chijioke Nze, Preetesh Jain, Ayushi Chauhan, Swami Iyer, Gita Masand, Jennifer Ramos, Christopher Flowers, Jason Westin, Dai Chihara

Blood (2025) 146 (Supplement 1): 5525.

https://doi.org/10.1182/blood-2025-5525

Published: 2025

Journal Articles

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3691.

https://doi.org/10.1182/blood-2025-3691

Published: 2025

Journal Articles

Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes

Rahul Shah, Zhiping Luo, Rhodora Fontillas, Betty Holder, Nicholas Szewczyk, Amy Ayers, Uday Popat, Elizabeth Shpall, Paolo Strati, Chijioke Nze, Preetesh Jain, Michael Wang, Jason Westin, Sattva Neelapu, Amy Ng, Ki Shin, Sairah Ahmed, An Ngo-Huang, Dai Chihara

Blood (2025) 146 (Supplement 1): 2719.

https://doi.org/10.1182/blood-2025-2719

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine: Phase 2 study

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy

Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Germline variants and their role in the pathogenesis of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) in adult lymphoma patients

Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma

A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma

Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only